Skip to main content

New Editor, New System

Both The Scientist and Nature's The Great Beyond Blog are reporting that Mehar Manku will be the new editor-in-chief of Elsevier's controversial journal Medical Hypotheses. Manku, who has since 2004 served as a member of the journal's editorial board, "vows to maintain the journal's unusual aim of distributing novel, radical ideas in medicine and related biomedical sciences while employing a more traditional peer review process than the journal saw under its previous editor," according to The Scientist. In addition to his new role, Manku is the executive editor and editor-in-chief of Prostaglandins, Leukotrienes and Essential Fatty Acids, as well as a part-time chief scientist at biopharmaceutical firm Amarin Corporation, The Scientist reports. Manku says in a statement that the Medical Hypotheses team "will engage a medically qualified editorial board to get members more involved in the review system to help ensure radical new ideas and speculations in medicine are given open-minded consideration while ensuring scientific merit."

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.